Duration of treatment for osteoporosis
- Luca Idolazzi Unità di Reumatologia, Dipartimento di Medicina, Università di Verona, Italy.
- A. Fassio Rheumatology Unit, University of Verona, Italy.
- D. Gatti Rheumatology Unit, University of Verona, Italy.
- S. Tamanini Rheumatology Unit, University of Verona, Italy.
- O. Viapiana
- M. Rossini
-
S. Adami
|
silvano.adami@univr.it
Abstract
Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness.
Downloads
Download data is not yet available.
Published
2013-03-28
Keywords:
Osteoporosis, duration, treatment, alendronate, denosumab.
Statistics
- Abstract views: 2953
- PDF: 947
How to Cite
Idolazzi, L., Fassio, A., Gatti, D., Tamanini, S., Viapiana, O., Rossini, M., & Adami, S. (2013). Duration of treatment for osteoporosis. Reumatismo, 65(1), 22-35. https://doi.org/10.4081/reumatismo.2013.22
Copyright (c) 2013 Luca Idolazzi, A. Fassio, D. Gatti, S. Tamanini, O. Viapiana, M. Rossini, S. Adami
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
